Piramal Pharma Share Price Target Tomorrow 2025 To 2030 Experts Analysis & Forecast

Piramal Pharma Share Price Target for 2025-2030 A Detailed Analysis: Piramal Pharma is a leading pharmaceutical company known for its significant presence in drug manufacturing, contract development, and healthcare solutions. With a robust international and domestic market footprint, Piramal Pharma focuses on specialty pharmaceuticals, active pharmaceutical ingredients (APIs), and consumer healthcare products. The company’s stock price on the National Stock Exchange (NSE) as of 2025, stands at ₹207.77 INR.

Piramal Pharma Share Details

Piramal Pharma Share Price Target Tomorrow 2025, 2026, 2027, 2028, 2029 To 2030

Piramal Pharma Share Price Target Tomorrow 2025 ₹310, 2026 ₹415, 2027 ₹509, 2028 ₹605, 2029 ₹710 To 2030 ₹812.

• Founded: 2020
• Headquarters: India
• Number of employees: 6,719 (2025)
• Subsidiaries: Piramal Critical Care, Piramal Critical Care Limited ·

Piramal Pharma Share Price Target 2025-2030

Piramal Pharma Share Price Target for 2025

Price Target: ₹310 INR

In 2025, Piramal Pharma’s share price is expect to reach ₹310 INR, marking a significant increase from its current value of ₹207.77 INR. This growth is anticipated to stem from strong revenue growth, positive market sentiment, and the company’s consistent track record in innovation and expansion. Piramal Pharma has been focused on expanding its global presence, securing approvals for new drugs, and increasing its market share. The ongoing demand for pharmaceuticals, especially in emerging markets, is expected to provide a boost to the company’s financial performance, helping the stock achieve this target.

Piramal Pharma Share Price Target for 2026

Price Target: ₹415 INR

For 2026, the target price for Piramal Pharma is project at ₹415 INR. This growth is support by continued innovation in its product portfolio and expansion into international markets. With increasing institutional interest and a strong foothold in the global pharmaceutical industry, Piramal Pharma’s future growth is poised for further acceleration. In this year, the company is expect to benefit from additional product approvals and robust financial results. Increased demand for its generic drugs and contract manufacturing services, coupled with strategic partnerships, will likely drive share price appreciation.

Piramal Pharma Share Price Target for 2027

Price Target: ₹509 INR

The share price target for Piramal Pharma in 2027 is ₹509 INR. By this time, the company is likely to experience significant revenue generation from new drug launches and successful clinical trials. Its investments in R&D will provide a competitive edge and lead to more global partnerships, propelling growth. The company’s focus on expanding its market share in both developed and emerging markets will likely boost revenue, while increasing operational efficiency could result in higher profitability. The stock price growth is expected to reflect these positive developments.

Piramal Pharma Share Price Target for 2028

Price Target: ₹605 INR

In 2028, the share price of Piramal Pharma is forecast to hit ₹605 INR. By this point, the company will likely see the fruits of its long-term investments in research, new drug approvals, and global expansion. With global healthcare demands on the rise and the company’s ability to diversify its product offerings, Piramal Pharma is expected to capitalize on the increasing demand for both specialty pharmaceuticals and over-the-counter products. Strong fundamentals and higher profitability will drive the company’s share price to this level.

Piramal Pharma Share Price Target for 2029

Price Target: ₹710 INR

By 2029, Piramal Pharma’s share price is anticipate to reach ₹710 INR, driven by continue global expansion and market penetration. As the company solidifies its position in the pharmaceutical industry, increased sales in key markets such as the U.S. and Europe will further contribute to stock price growth. Ongoing regulatory approvals, new product lines, and increased institutional investments will help maintain investor confidence, propelling Piramal Pharma’s stock value upwards over the next few years.

Piramal Pharma Share Price Target for 2030

Price Target: ₹812 INR

The project target for Piramal Pharma’s share price in 2030 is ₹812 INR. As the company approaches this milestone, it is expect to have a robust portfolio of patented drugs, expanded global markets, and solid operational efficiency.

The pharmaceutical sector’s growth, combined with Piramal Pharma’s ability to manage regulatory challenges and capitalize on new opportunities, will help achieve this substantial increase. Its strategic focus on high-margin products and consistent earnings growth will further fuel investor confidence, propelling the stock price to ₹812 INR.

Piramal Pharma Shareholding Pattern

The company’s shareholding pattern is as follows:

Key Factors Affecting Piramal Pharma Share Price Growth

• Revenue and Profit Growth: Steady revenue and profit growth strengthens investor confidence. Continued market expansion, innovative products, and improved efficiencies can positively affect earnings, driving up the share price.
• New Drug Approvals and R&D Innovations: Successful clinical trials and the approval of new medicines are pivotal in propelling growth. Strong R&D and a competitive product pipeline can significantly boost stock prices as the company gains a market edge.
• Expansion in Global Markets: Piramal Pharma’s efforts to increase its presence in international markets, especially in the U.S. and Europe, contribute to higher sales and overall profitability. Strategic acquisitions and partnerships will also aid in expanding its footprint.
• Regulatory Compliance and Certifications: Maintaining high-quality standards and securing approvals from global regulatory bodies, such as the U.S. FDA and WHO, enhances the company’s reputation. Strong regulatory compliance reduces operational risks, building investor confidence.
• Growing Demand for Healthcare and Pharmaceuticals: With rising healthcare awareness and an increasing demand for medications, Piramal Pharma stands to benefit from expanding global pharmaceutical needs, boosting its share price growth prospects.
• Cost Management and Operational Efficiency: Efficient cost management, improved supply chains, and better control over raw material costs contribute to higher profit margins. The company’s ability to keep operational expenses under control will ensure sustained profitability.
• Market Sentiment and Institutional Investments: Investor sentiment plays a crucial role in driving stock prices. Positive analyst ratings and growing institutional investments can support Piramal Pharma’s long-term growth trajectory.

Risks and Challenges for Piramal Pharma Share Price

• Regulatory and Compliance Risks: The pharmaceutical industry’s heavy regulations mean any failure to meet global quality standards could lead to fines or product recalls, negatively impacting the company’s stock value.
• Pricing Pressure and Competition: The pharma sector is highly competitive. Pricing pressures, particularly from generic drug makers, could negatively affect Piramal Pharma’s profit margins, making it harder to maintain growth.
• Dependence on Key Markets: Piramal Pharma relies on key markets like the U.S. and Europe. Any geopolitical or regulatory changes in these regions could significantly impact sales and profitability.
• Raw Material and Supply Chain Disruptions: Disruptions in the supply chain or an increase in the cost of raw materials could affect production costs and reduce profit margins, posing a risk to share price growth.
• High R&D Costs and Uncertain Approvals: Developing new drugs involves substantial costs with no guarantee of success. Failed trials or delayed regulatory approvals could result in financial losses, which might undermine investor confidence.
• Debt and Financial Burden: Excessive debt due to expansion or acquisitions can create financial pressure on Piramal Pharma. High interest payments and financial obligations may reduce profitability and limit growth.
• Market Volatility and Investor Sentiment: Stock price fluctuations due to broader economic downturns or adverse market conditions can affect investor confidence and lead to short-term stock price declines, even if the company performs well operationally.

Is Piramal Pharma a good company?

Piramal Pharma is rated 4.0 out of 5 stars on Ambition Box, based on 999 company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities.

Who is the owner of Piramal Pharma?

Mr. Ajay Piramal is one of India’s leading industrialists and philanthropists, and Chairman of the Piramal Group. Piramal Group is a global business conglomerate with diverse interests in pharmaceuticals, financial services and real estate, with offices in 30 countries and its products sold in more than 100 markets.

 Is Piramal Pharma debt free?

Piramal Pharma has a total shareholder equity of ₹79.1B and total debt of ₹47.9B, which brings its debt-to-equity ratio to 60.5%. Its total assets and total liabilities are ₹152.4B and ₹73.3B respectively. Piramal Pharma’s EBIT is ₹6.5B making its interest coverage ratio 1.5.

            Pivot = Previous Close
            Resistance_n = Pivot + (Range × F_n)
            Support_n = Pivot - (Range × F_n)
        

            Average Return = (1/N) Σ R_i
        

            σ = √[(1/(N-1)) Σ (R_i - μ)^2]
        

            Target Price_next month = Current Price × (1 + Adjusted Growth Rate)